The FY2027 appropriations process gives Congress an immediate opportunity to protect medical cannabis patients from discrimination while addressing the gaps left by the Attorney General's order. Through funding directives, legislative provisions, and committee report language, Congress can require federal agencies to protect patients, update outdated policies, and establish the safeguards necessary for safe access and healthcare integration. These actions cannot replace comprehensive medical cannabis legislation, but they can help ensure that patients are not left behind while Congress develops a national framework.

For ASA's complete appropriations agenda, detailed requests across all seven subcommittees, and the latest congressional developments, visit our FY2027 Medical Cannabis Appropriations Hub. We will update the hub as Congress considers FY2027 funding legislation and patient advocacy opportunities.

DOWNLOAD PROPOSED HUD APPROPS LANGUAGE | TAKE ACTION

 

PATIENTS NEED THE SUBCOMMITTEE TO ACT

The Department of Housing and Urban Development (HUD) continues to rely on medical cannabis policies developed when federal law classified cannabis as having no accepted medical use. Although Attorney General Order No. 6754-2026 established a federal registration pathway for qualifying medical cannabis products, HUD has not comprehensively updated its guidance to address the changing federal framework. Patients participating in state-authorized medical cannabis programs may still face denial of admission, eviction, termination of housing assistance, lease nonrenewal, or refusal of reasonable accommodation.

Federal housing law presents particular challenges because it distinguishes admission requirements from continued occupancy. Under 42 U.S.C. § 13661, housing agencies and owners must establish standards prohibiting admission when a household member is determined to be illegally consuming a controlled substance. Section 13662 requires standards that allow termination of assistance or tenancy under specified circumstances but provides discretion on whether to terminate an existing tenancy. The Attorney General's order does not independently repeal these requirements, so HUD must distinguish statutory mandates from policies it can revise administratively.

These policies affect patients with disabilities, seniors, veterans, low-income households, and people managing serious or chronic medical conditions. Congress should direct HUD to review outdated policies, clarify how existing federal housing and disability laws apply, and establish procedures for individualized housing decisions wherever federal law permits. Participation in a state-authorized medical cannabis program should not, by itself, be treated as proof of prohibited conduct or grounds for automatic exclusion when such exclusion is not required by federal law.

ASA'S FY2027 APPROPRIATIONS REQUEST

Americans for Safe Access requests that Congress direct HUD to conduct a comprehensive review of its medical cannabis policies and withdraw, replace, or revise outdated guidance within its existing legal authority. The review should address admissions, continued occupancy, evictions, termination of assistance, lease renewals, reasonable accommodation requests, and the treatment of qualifying medical cannabis patients and caregivers.

HUD should also identify restrictions that cannot be changed administratively, recommend necessary statutory amendments, and provide consistent guidance and training to public housing agencies, assisted-property owners, and program administrators. The objective is to prevent unnecessary housing disruption and categorical patient exclusions while preserving lawful program requirements, individualized disability protections, and legitimate health and safety standards.

PROPOSED BILL LANGUAGE

SEC. __. DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT MEDICAL CANNABIS POLICY REVIEW AND PATIENT HOUSING PROTECTIONS.

(a) Review and Revision of Existing Guidance. Not later than 60 days after the date of enactment of this Act, the Secretary of Housing and Urban Development shall review and, to the extent permitted by applicable federal law, withdraw, revise, or supersede existing departmental guidance that categorically excludes individuals solely because they participate in state-authorized medical cannabis programs.

The review shall include the December 29, 2014 memorandum entitled Use of Marijuana in Multifamily Assisted Properties; the February 10, 2011 guidance concerning public housing and Housing Choice Voucher programs; existing medical marijuana reasonable-accommodation guidance; and related notices, handbooks, lease provisions, admission standards, occupancy policies, and administrative instructions.

Updated guidance shall address public housing, Housing Choice Voucher programs, and multifamily assisted housing. It shall distinguish participation in a state-authorized medical cannabis program, caregiver administration, applicable federal statutory requirements, documented lease violations, and legitimate health or safety concerns.

(b) Regulatory Review and Statutory Barriers. The Secretary shall review 24 C.F.R. §§ 960.204 and 5.854, related continued-occupancy regulations, and the application of 42 U.S.C. §§ 13661 and 13662 to qualifying medical cannabis patients and caregivers.

The review shall assess the relationship between the federal medical cannabis framework and applicable provisions of the Fair Housing Act and Section 504 of the Rehabilitation Act. It shall identify policies that may be revised through guidance or rulemaking, distinguish mandatory statutory restrictions from discretionary administrative decisions, and recommend legislative changes needed to address protections that cannot be established under existing law.

(c) Individualized Housing Review and Patient Protections. The Secretary shall issue guidance, consistent with applicable federal law, directing public housing agencies, assisted-property owners, and program administrators to evaluate medical cannabis-related housing determinations through individualized review wherever such review is authorized.

Such guidance shall address state-authorized patient and caregiver status, disability accommodation requests, documented safety concerns, actual lease violations, admission and continued-occupancy standards, and relevant appeal procedures. It shall distinguish evidence of prohibited conduct from participation in a medical cannabis program and preserve applicable federal restrictions governing illegal drug activity and threats to the health, safety, or peaceful enjoyment of other residents.

(d) Implementation and Congressional Oversight. Not later than 60 days after enactment, the Secretary shall provide the Committees on Appropriations with a summary of the guidance reviewed, revised, or withdrawn; notifications and training provided or planned for public housing agencies and assisted-housing administrators; anticipated regulatory actions; and any provisions of federal law that may require congressional amendment.

The Secretary shall provide updated program instructions to relevant housing providers and administrators and identify steps needed to revise admissions forms, lease provisions, occupancy policies, resident notices, reasonable-accommodation procedures, and other materials affected by the review.

PROPOSED COMMITTEE REPORT LANGUAGE

Medical Cannabis Patient Housing Protections and Federal Housing Guidance

The Committee recognizes that federal medical cannabis policy has changed substantially while HUD guidance governing state-authorized medical cannabis patients has not been comprehensively updated. The Committee directs HUD to review its existing policies concerning medical cannabis in federally assisted housing and submit a report within 60 days after enactment addressing the following matters:

(a) Federal Policy and Statutory Review. HUD shall evaluate the application of Attorney General Order No. 6754-2026 to public housing, Housing Choice Voucher programs, and multifamily assisted housing. The report shall identify applicable statutory admission and termination requirements, discretionary housing decisions, regulations requiring revision, anticipated rulemaking, and legislative amendments needed to prevent patient exclusions that existing administrative authority cannot address.

(b) Patient and Caregiver Protections. HUD shall identify opportunities under existing federal law to ensure individualized consideration of qualifying medical cannabis patients and caregivers in admission, continued occupancy, termination, eviction, lease nonrenewal, and reasonable-accommodation decisions. The review shall address disability protections, actual conduct, documented safety concerns, and applicable statutory limitations without treating state medical cannabis program participation alone as evidence of unlawful conduct.

(c) Implementation and Training. HUD shall develop model guidance, application and appeal procedures, and training recommendations for public housing agencies, assisted-property owners, and program administrators. The report shall describe how HUD will communicate updated standards, monitor implementation, identify unresolved barriers, and provide Congress with recommendations for any additional statutory protections.

DOWNLOAD PROPOSED HUD APPROPS LANGUAGE | TAKE ACTION

THE PATH FORWARD

The priorities outlined here are part of Americans for Safe Access' coordinated FY2027 appropriations agenda across seven congressional subcommittees. Together, these requests seek to protect patients, remove discriminatory barriers, strengthen federal accountability, and establish the policies necessary to integrate medical cannabis into American healthcare.

Congress can take meaningful action through the appropriations process while laying the groundwork for comprehensive medical cannabis legislation in the 120th Congress. Patients should not have to choose between the medicine they rely on and their healthcare, housing, livelihoods, or fundamental rights. Explore ASA's complete FY2027 Medical Cannabis Appropriations Agenda to learn how these requests work together and follow the latest congressional developments.

The Path Forward: The Medical Cannabis & Cannabinoid Act 

 References & Sources

91 FR 22714

DEA Marijuana Rescheduling Regulatory Actions

CRS LSB11496 (Oct. 28, 2026)